Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
SUPPLEMENT ARTICLE How Science Will Help Shape Future Clinical Applications of Probiotics Gregor Reid Canadian Research and Development Centre for Probiotics, Lawson Health Research Institute, and Department of Microbiology and Immunology and Department of Surgery, Schulich School of Medicine and Dentistry, The University of Western Ontario, London, Canada The recent increased interest in probiotics among clinicians has many causes, primarily the concern about the limitations of the current armamentarium of pharmaceutical agents. Although probiotics have been used mostly in dietary supplements and foods to maintain health, scientific and clinical studies are recognizing the potential of some probiotics to be therapeutic in function. Scientific breakthroughs in understanding the source and composition of the human microbiota, the key nutritional factors that influence these microbes, and their immunomodulatory effects; the creation of disease-targeted recombinant strains; the isolation and characterization of signaling molecules that can modulate microbial biofilms and infectious processes; and advances in biomedical engineering that will provide new delivery systems for probiotics will shape the future of clinical applications of probiotics. In time and with rigorous documentation, some probiotics will likely find an important place in medical practice. WHAT ARE PROBIOTICS? In 2001, an expert-panel report from the United Nations and the World Health Organization finally provided a definition of probiotics that embraced the breadth of their applications and emphasized the need for clinical documentation of the benefits they confer [1]. This definition is “live microorganisms which when administered in adequate amounts confer a health benefit on the host” [1, p. 5]. The subsequent guidelines published jointly by both international organizations [2] and later endorsed by the International Scientific Association for Probiotics and Prebiotics [3] gave scientific, clinical, and manufacturing standards that need to be met for products to be called “probiotic.” Such is the nature of these guidelines that they provide the means for developing new strains and new applications. In this short review, 5 examples are provided to illustrate how scientific advances will likely lead to new and Reprints or correspondence: Dr. Gregor Reid, Canadian Research and Development Centre for Probiotics, F2-116 Lawson Health Research Institute, 268 Grosvenor St., London, Ontario, N6A 4V2 Canada ([email protected]). Clinical Infectious Diseases 2008; 46:S62–6 2008 by the Infectious Diseases Society of America. All rights reserved. 1058-4838/2008/4603S2-0003$15.00 DOI: 10.1086/523340 S62 • CID 2008:46 (Suppl 2) • Reid potentially exciting breakthroughs that will have farreaching benefits for many humans and animals. THE ORIGIN OF OUR MICROBIOTA More than 500 million years ago, Earth was inhabited only by single-cell microbes. It can be argued that humans thus emerged from bacteria and that bacteria actually “permitted” this to occur, in the sense that they could have eradicated the human race on many occasions but did not. There is no question that microbes influence health, as the study of infectious disease pathogens has long shown. However, less well understood are the beneficial microbes, their origin before they colonized humans, and their role in retention of good health in a host. With 125% of humans born by cesarean delivery and, therefore, not exposed as newborns to the microbiota of the mother’s vaginal and rectal areas, one would assume that the microbial composition of humans varies profoundly. Given that the microbiota tend to stabilize within the first year of life and that, thereafter, it is difficult for exogenous organisms to take a foothold [4, 5], it is critical to determine the source of the organisms that humans inherit. Elegant animal studies have been performed on Bacteroides thetaiotaomicron and Bacteroides fragilis, show- ing their importance in the development of healthy intestinal and immune systems, respectively [6, 7]. In humans, however, where do these organisms come from? In a study of the microbiota of 2 newborns, B. thetaiotaomicron was detected early in life in 1 child [8]. This anaerobe is found in the intestine, but how would it be passed to a baby born by cesarean delivery, and what would be the consequence of it not being present? Perhaps these organisms come from the environment and are passed to the baby by handling or kissing or are received by the baby putting objects in his or her mouth. Without basic microbiological studies, we cannot be sure. To date, there have been no studies that compare the gut microbiota between infants born vaginally and infants born by cesarean section or between infants breast-fed and infants fed with formula, and there has been no long-term follow-up to determine whether and how these differences may affect health outcomes. Such studies would be difficult to undertake, and some people might think they do not have value because, epidemiologically, there have not been major differences noted between the health and longevity of adults in one category of infants and those in another category. Nevertheless, just as Barker’s [9] long-term studies unexpectedly discovered a link between maternal health during gestation and adulthood illness, so too might microbiota differences in species types and microbial numbers lead to insight into the critical problems that face the current health care system because of syndrome X. Already, a link between microbes has been reported for obesity [10] and ankylosing spondylitis [11]. Whether probiotic intervention can alter such clinical outcomes remains to be seen. The finding of lactobacilli in breast milk [12] has led to the suggestion that M or dendritic cells sample the microbiota, pick up these strains, and then transfer them into the mammary duct, through which they pass to the baby. If that were true, presumably Bacteroides species could be transferred likewise. Several molecular techniques have been developed to identify and track changes in microbiota in human, animal, and environmental samples [13–15]. Although it is a tedious task, studies are needed to determine where the constituents of our microbiota come from in the environment. The “hygiene hypothesis” suggests that lack of exposure to certain organisms could be partly responsible for increased rates of some chronic diseases, such as allergies [16]. If we understood the types of organisms whose inheritance significantly enhanced health, appropriate strategies could be developed for delivery of probiotics in a more systematic way, rather than in the random method used to date. Such approaches have major ethical considerations and are unlikely to occur in the next 10 years. However, just as human genomics will lead to interventions in utero and at different stages in life (e.g., performance of prophylactic mastectomy for women at high risk of cancer and death), so too might selective use of probiotics be applied to alter progression of disease. DIETARY FACTORS Genetically, humans are virtually the same as they were at the end of Paleolithic times ∼20,000 years ago, yet the development of agriculture and domestication of animals ∼10,000 years ago and the Industrial Revolution 200 years ago brought new dietary practices and pressures [17]. Historical and anthropological studies claim that huntergatherers were generally healthy, fit, and largely free of the degenerative cardiovascular diseases common in modern societies. Life spans were short, but this was because of infectious disease, predators, and fighting, rather than heart disease or diabetes. Since those times, the energy requirements of an enlarged brain have coincided with a reduction in the size and energy requirements of the digestive system, which leads to the postulate that changes in food staples and food-processing procedures have altered crucial nutritional characteristics of our ancestral diet—namely, glycemic load, fatty-acid level, macronutrient balance, trace nutrient density, acid-base balance, sodium-potassium balance, and fiber content [17–19]. Prebiotics are nondigestible substances that provide a beneficial physiological effect on the host by selectively stimulating the favorable growth or activity of a limited number of indigenous bacteria [1]. Ancient humans ate many sources of prebiotics (e.g., plant roots) and used fermentation as a means of food preservation and preparation. To design new foods either to deliver probiotic or prebiotic products or to intentionally and specifically modify the intestinal microbiota as a means of lowering rates of chronic disease, we might want to assess a maternal diet supplemented with prebiotics or fermented foods and plant roots and see whether it alters mammary levels of Lactobacillus organisms or other species. Also, such diets could be tested during weaning to see whether they modify the gut microbiota or susceptibility to asthma and allergy. Studies of babies are difficult for ethical reasons, and it is impossible to know exactly what the Paleolithic diet was and whether it was advantageous to the health of babies. Nevertheless, diet and microbes influence the fundamental aspects of immunity and development, yet we know so little about how we acquire bacteria and which ones should be supplemented to achieve shortand long-term good health. In due course, new symbiotic products (i.e., mixtures of probiotics and prebiotics) will be developed to improve the acquisition of healthy gut microbiota, assuming that such microbiota exist. ALTERING THE COURSE OF DISEASE There are many examples of pharmaceutical and dietary interventions that have fundamentally altered the course of disease. It is difficult to know the extent to which this applies to The Future of Probiotics • CID 2008:46 (Suppl 2) • S63 probiotics, but their use in alleviating diarrhea is at least 1 indication of their potential. This application could have a profound effect on the quality of life of people with HIV infection or AIDS, among whom chronic diarrhea is commonplace and often contributes to death. In one study, 40 HIV-infected patients who were taking a stavudine- and/or didanosine-based HAART regimen were prospectively randomized to receive micronutrients or placebo twice daily for 12 weeks. The absolute CD4 cell count increased by an average of 24% in the group receiving micronutrients, compared with a 0% change in the placebo group (P p .01) [20]. This study did not assess the impact of the micronutrients on the gut microbiota or immunity per se, and it would be interesting to perform such an assessment, especially with prebiotics added to the micronutrients. In a second randomized, placebo-controlled study of 24 subjects with HIV infection or AIDS, daily ingestion of probiotic Lactobacillus rhamnosus GR1 and Lactobacillus reuteri RC-14, supplemented in yogurt, led to rapid resolution of diarrhea, flatulence, and nausea, as well as a small increase in CD4 cell counts [21]. For the vast majority of patients with AIDS who cannot gain access to antiretroviral therapies or who cannot take them because they have insufficient food intake to avoid the major adverse effects of the drugs, the use of relatively simple foods and supplements could have significant benefits. The increase in CD4 cell counts found after consumption of nutrients and probiotics needs to be further confirmed in larger studies, but this approach could affect a significant number of patients with AIDS. Another major disease that affects a large amount of the world’s population is diabetes. Some preliminary data suggest that probiotics may lengthen the time to onset of type I diabetes [22]. The mechanisms are unclear, but, given the anti-inflammatory effects [23] of the probiotics used in that study, it seems feasible that modulation of immunity plays a role. Integration of human IL-10 genes into lactococci has led to the creation of an organism that appears able to alleviate inflammatory processes in the gut of humans [24]. The link between antiinflammatory lactic acid bacteria and alteration of the course of diabetes is still far from proven, but any condition influenced so greatly by diet is surely also affected by the microbiota in the gut, and alteration of these organisms is at least worthy of investigation. During the crisis of severe acute respiratory syndrome, sales of certain probiotics increased substantially in Hong Kong, apparently because of the perception that they could enhance immunity. In fact, there are a number of studies that show improved recovery from respiratory infections with use of orally administered probiotics [25–30]. This implies modulation of immunity and distant site effects of ingested microbes. The use of probiotics to mitigate or augment the treatment of avian influenza or other major respiratory infections is worth invesS64 • CID 2008:46 (Suppl 2) • Reid tigating, especially since antiviral therapies may not work for, or be available to, the populations of people infected. As a first step, studies are needed to understand whether and how probiotic organisms alter susceptibility of the respiratory tract to disease. BIOFILMS AND SIGNALING The growing rates of antibiotic resistance and the realization that biofilm formation makes it more difficult for antibiotics to eradicate infections have led to studies of new approaches to managing infectious biofilms. These include disruption or penetration of biofilms by beneficial microbes or alteration of the environment to restore a noninfectious biofilm. The relatively short interval during which a vaginal microbiota can change from one dominated by lactobacilli to one dominated by anaerobic gram-negative pathogens that cause bacterial vaginosis provides a good model system to study these issues. The failure of metronidazole to cure bacterial vaginosis in some cases [31] and the finding of clue cells covered in dense biofilms within 3 weeks after treatment would suggest an inability of the drug to eradicate biofilms. This is particularly likely given that major resistance of planktonic vaginosis bacteria to metronidazole has not been reported. An in vitro study has shown that Gardnerella vaginalis biofilms can be penetrated by L. rhamnosus GR-1, leading to rapid disruption and death of the pathogens [32]. This correlates with human studies in which Gardnerella species are displaced [33] and bacterial vaginosis is cured [34] by probiotic lactobacilli. Other studies have shown that this Lactobacillus strain can also prevent Candida albicans biofilms from forming, and it can kill the yeast in vitro [35]. In the near future, fluorescent in situ hybridization and confocal laser microscopy, used successfully to study complex oral biofilms, will be used to better understand how gramnegative and gram-positive bacteria interact in biofilms and are affected by different nutrients [36]. Within dense multispecies biofilms, it is clear that several communication tools are used. Quorum-sensing molecules, such as autoinducers, provide information that helps microbe populations modulate growth, expression of virulence factors, and formation of biofilms [37–39]. The discovery of a signal produced by L. reuteri RC-14, which significantly down-regulates exotoxin production by Staphylococcus aureus [40], is the cusp of a new and exciting field that will see many signaling molecules identified that potentially can be used to prevent and treat infections in the future. Likewise, factors that influence host cells—such as those produced by B. thetaiotaomicron, which affect Paneth cells [6], and those produced by lactobacilli that induce mucin production [41] and down-regulate inflammatory processes [42]—will in due course become part of the new biotechnological approach to patient care. Using an Affymetrix gene array, we have recently shown that L. rhamnosus GR-1 instillation into the vagina is associated with up-regulation of some host defense factors (authors’ unpublished data). By the combination of human gene-array studies with the application of defined, genome-sequenced probiotic organisms, it will be possible to more optimally target specific probiotic strains to specific patients or conditions. DELIVERY MECHANISMS Advances in biomedical engineering will prove to be equally important to molecular biology in terms of the developing systems that deliver bacteria and/or nutritional factors to the host. These will include encapsulating probiotics, such that they rehydrate at specific sites, and encasing prebiotics in nanoaggregates that protect against stomach acid and deliver their payload when the pH reaches 7.4 [43]. Potentially, such nanoencapsulation will also allow delivery in foods such as biscuits, whereas targeted, water-protected macrocapsules containing probiotic organisms may prove useful in animal food pellets and perhaps in liquids, which currently cannot be used because of problems with shelf stability. At the macromolecular level, it will soon be possible to coat capsules with biosensors that detect the optimal conditions for release of probiotic contents. Likewise, recombinant strains will be created to respond to specific triggers in a host (e.g., a pathogen’s toxin) and produce factors to counteract them. Such sensors are already being described, such as the repressor FucR in B. thetaiotaomicron, which responds to l-fucose availability [44]. The Given Imaging’s PillCam is a good example of engineering technology in medicine. This tiny capsule is swallowed, and, as it passes through the host, it takes photographs of the mucosal tissues. In time, such devices will be controlled remotely, will have sensors and sampling devices, and will deliver payloads at the desired site. Such science fiction will become reality within 10 years. In summary, molecular, nano, biochemical, microbiological, immunological, and engineering sciences hold the key to future advances in the clinical application of probiotic and prebiotic products. To make these breakthroughs of value to patients, companies in the food, biotechnology, engineering, and pharmaceutical industries will have to learn from each other with regard to production of strains and their delivery-suitable formulations, while traditionally bureaucratic and slow-moving regulatory agencies will have to become visionary, proactive, and more adept at processing these new developments. Unless this happens, the great strides made in science may never reach the people who need it the most. Acknowledgments The assistance of the International Scientific Association for Probiotics and Prebiotics is appreciated. Financial support. Ontario Ministry of Agriculture and Food. Supplement sponsorship. This article was published as part of a sup- plement entitled “Developing Probiotics as Foods and Drugs: Scientific and Regulatory Challenges,” sponsored by the Drug Information Association, the National Institutes of Health National Center for Complementary and Alternative Medicine (1R13AT003805-01 to Patricia L. Hibberd), the California Dairy Research Foundation, Chr. Hansen, the Dannon Company, General Mills, Institut Rosell, and Yakult International. Potential conflicts of interest. G.R. has received recent research funding from Wyeth Aherst and Otsuka, owns patents licensed to Chr. Hansen for probiotics for women’s health, and owns patents on the use of Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 for urogenital health. References 1. Joint FAO/WHO Expert Consultation on Evaluation of Health and Nutritional Properties of Probiotics in Food Including Powder Milk with Live Lactic Acid Bacteria. Health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria: report of a Joint FAO/WHO Expert Consultation on Evaluation of Health and Nutritional Properties of Probiotics in Food Including Powder Milk with Live Lactic Acid Bacteria, Córdoba, Argentina, 1–4 October 2001. Available at: ftp://ftp.fao.org/es/esn/food/probio_re port_en.pdf. Accessed 10 December 2007. 2. Joint FAO/WHO Working Group on Drafting Guidelines for the Evaluation of Probiotics in Food. Guidelines for the evaluation of probiotics in food: report of a Joint FAO/WHO Working Group on Drafting Guidelines for the Evaluation of Probiotics in Food, London, Ontario, Canada, April 30 and May 1, 2002. Available at: ftp://ftp.fao.org/es/ esn/food/wgreport2.pdf. Accessed 10 December 2007. 3. Reid G, Sanders ME, Gaskins HR, et al. New scientific paradigms for probiotics and prebiotics. J Clin Gastroenterol 2003; 37:105–18. 4. Fanaro S, Chierici R, Guerrini P, Vigi V. Intestinal microflora in early infancy: composition and development. Acta Paediatr 2003; 91(Suppl): 48–55. 5. Bourlioux P, Koletzko B, Guarner F, Braesco V. The intestine and its microflora are partners for the protection of the host: report on the Danone symposium “The Intelligent Intestine,” held in Paris, June 14, 2002. Am J Clin Nutr 2003; 78:675–83. 6. Stappenbeck TS, Hooper LV, Gordon JI. Developmental regulation of intestinal angiogenesis by indigenous microbes via Paneth cells. Proc Natl Acad Sci U S A 2002; 99:15451–5. 7. Mazmanian SK, Liu CH, Tzianabos AO, Kasper DL. An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell 2005; 122:107–18. 8. Favier CF, Vaughan EE, De Vos WM, Akkermans AD. Molecular monitoring of succession of bacterial communities in human neonates. Appl Environ Microbiol 2002; 68:219–26. 9. Barker DJ. The fetal and infant origins of adult disease. BMJ 1990; 301:1111. 10. Backhed F, Manchester JK, Semenkovich CF, Gordon JI. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci U S A 2007; 104:979–84. 11. Stebbings S, Munro K, Simon MA, et al. Comparison of the faecal microflora of patients with ankylosing spondylitis and controls using molecular methods of analysis. Rheumatology (Oxford) 2002; 41: 1395–401. 12. Martin R, Olivares M, Marin ML, Fernandez L, Xaus J, Rodriguez JM. Probiotic potential of 3 lactobacilli strains isolated from breast milk. J Hum Lact 2005; 21:8–17. 13. Burton JP, Reid G. Evaluation of the bacterial vaginal flora of 20 postmenopausal women by direct (Nugent score) and molecular (polymerase chain reaction and denaturing gradient gel electrophoresis) techniques. J Infect Dis 2002; 186:1770–80. 14. Fredricks DN, Fiedler TL, Marrazzo JM. Molecular identification of bacteria associated with bacterial vaginosis. N Engl J Med 2005; 353: 1899–911. 15. Zabarovska V, Kutsenko AS, Petrenko L, et al. NotI passporting to The Future of Probiotics • CID 2008:46 (Suppl 2) • S65 16. 17. 18. 19. 20. 21. 22. 23. 24. 25. 26. 27. 28. 29. 30. identify species composition of complex microbial systems. Nucleic Acids Res 2003; 31:E5. Guarner F, Bourdet-Sicard R, Brandtzaeg P, et al. Mechanisms of disease: the hygiene hypothesis revisited. Nat Clin Pract Gastroenterol Hepatol 2006; 3:275–84. Mann NJ. Paleolithic nutrition: what can we learn from the past? Asia Pac J Clin Nutr 2004; 13(Suppl):S17. O’Keefe JH Jr, Cordain L. Cardiovascular disease resulting from a diet and lifestyle at odds with our Paleolithic genome: how to become a 21st-century hunter-gatherer. Mayo Clin Proc 2004; 79:101–8. Stiner MC. Thirty years on the “broad spectrum revolution” and paleolithic demography. Proc Nat Acad Sci U S A 2001; 98:6993–6. Kaiser JD, Campa AM, Ondercin JP, Leoung GS, Pless RF, Baum MK. Micronutrient supplementation increases CD4 count in HIV-infected individuals on highly active antiretroviral therapy: a prospective, double-blinded, placebo-controlled trial. J Acquir Immune Defic Syndr 2006; 42:523–8. Anukam KC, Osazuwa EO, Osadolor BE, Bruce AW, Reid G. Yogurt containing probiotic Lactobacillus rhamnosus GR-1 and L. reuteri RC14 helps resolve moderate diarrhea and increases CD4 count in HIV/ AIDS patients. J Clin Gastroenterol (in press). Calcinaro F, Dionisi S, Marinaro M, et al. Oral probiotic administration induces interleukin-10 production and prevents spontaneous autoimmune diabetes in the non-obese diabetic mouse. Diabetologia 2005; 48:1565–75. Hart AL, Lammers K, Brigidi P, et al. Modulation of human dendritic cell phenotype and function by probiotic bacteria. Gut 2004; 53:1602–9. Braat H, Rottiers P, Hommes DW, et al. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn’s disease. Clin Gastroenterol Hepatol 2006; 4:754–9. Tubelius P, Stan V, Zachrisson A. Increasing work-place healthiness with the probiotic Lactobacillus reuteri: a randomised, double-blind placebo-controlled study. Environ Health 2005; 4:25. Gill HS, Rutherfurd KJ, Cross ML, Gopal PK. Enhancement of immunity in the elderly by dietary supplementation with the probiotic Bifidobacterium lactis HN019. Am J Clin Nutr 2001; 74:833–9. Lykova EA, Vorob’ev AA, Bokovoi AG, Murashova AO. Impaired interferon status in children with acute respiratory infection and its correction with Bifidumbacterin-forte. Zh Mikrobiol Epidemiol Immunobiol 2001; Mar-Apr:65–7. Gluck U, Gebbers JO. Ingested probiotics reduce nasal colonization with pathogenic bacteria (Staphylococcus aureus, Streptococcus pneumoniae, and b-hemolytic streptococci). Am J Clin Nutr 2003; 77: 517–20. Hatakka K, Savilahti E, Ponka A, et al. Effect of long term consumption of probiotic milk on infections in children attending day care centres: double blind, randomised trial. BMJ 2001; 322:1327. Turchet P, Laurenzano M, Auboiron S, Antoine JM. Effect of fermented milk containing the probiotic Lactobacillus casei DN-114001 on winter S66 • CID 2008:46 (Suppl 2) • Reid 31. 32. 33. 34. 35. 36. 37. 38. 39. 40. 41. 42. 43. 44. infections in free-living elderly subjects: a randomised, controlled pilot study. J Nutr Health Aging 2003; 7:75–7. Anukam K, Osazuwa E, Ahonkhai I, et al. Augmentation of antimicrobial metronidazole therapy of bacterial vaginosis with oral probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14: randomized, double-blind, placebo controlled trial. Microbes Infect 2006; 8:1450–4. Saunders SG, Bocking A, Challis J, Reid G. Disruption of Gardnerella vaginalis biofilms by Lactobacillus. Colloids Surf B Biointerfaces 2007; 55:138–42. Burton JP, Cadieux PA, Reid G. Improved understanding of the bacterial vaginal microbiota of women before and after probiotic instillation. Appl Environ Microbiol 2003; 69:97–101. Anukam KC, Osazuwa E, Osemene GI, Ehigiagbe F, Bruce AW, Reid G. Clinical study comparing probiotic Lactobacillus GR-1 and RC-14 with metronidazole vaginal gel to treat symptomatic bacterial vaginosis. Microbes Infect 2006; 8:2772–6. Kohler GA, Reid G. Mechanisms of probiotic interference with Candida albicans [abstract C126]. In: Program and abstracts of the 8th American Society of Microbiology Conference on Candida and Candidiasis (Denver). 2006:79. Thurnheer T, Gmur R, Guggenheim B. Multiplex FISH analysis of a six-species bacterial biofilm. J Microbiol Methods 2004; 56:37–47. Shiner EK, Rumbaugh KP, Williams SC. Inter-kingdom signaling: deciphering the language of acyl homoserine lactones. FEMS Microbiol Rev 2005; 29:935–47. ten Cate JM. Biofilms, a new approach to the microbiology of dental plaque. Odontology 2006; 94:1–9. Mittal R, Sharma S, Chhibber S, Harjai K. Contribution of quorumsensing systems to virulence of Pseudomonas aeruginosa in an experimental pyelonephritis model. J Microbiol Immunol Infect 2006; 39: 302–9. Laughton JM, Devillard E, Heinrichs DE, Reid G, McCormick JK. Inhibition of expression of a staphylococcal superantigen-like protein by a soluble factor from Lactobacillus reuteri. Microbiology 2006; 152: 1155–67. Mack DR, Ahrne S, Hyde L, Wei S, Hollingsworth MA. Extracellular MUC3 mucin secretion follows adherence of Lactobacillus strains to intestinal epithelial cells in vitro. Gut 2003; 52:827–33. Kim SO, Sheikh HI, Ha SD, Martins A, Reid G. G-CSF–mediated inhibition of JNK is a key mechanism for Lactobacillus rhamnosus–induced suppression of TNF production in macrophages. Cell Microbiol 2006; 8:1958–71. Fan YF, Wang YN, Fan YG, Ma JB. Preparation of insulin nanoparticles and their encapsulation with biodegradable polyelectrolytes via the layer-by-layer adsorption. Int J Pharm 2006; 324:158–67. Hooper LV, Xu J, Falk PG, Midtvedt T, Gordon JI. A molecular sensor that allows a gut commensal to control its nutrient foundation in a competitive ecosystem. Proc Natl Acad Sci U S A 1999; 96:9833–8.